In vivo experiments demonstrated a significantly higher subcutaneous tumor incidence rate in the CD133+ group (26/30) compared with the CD133− group (2/30) following inguinal subcutaneous inoculation of CD133+ or CD133− glioblastoma cells into thymectomized mice. This evidence concerns the gene PROM1 and neoplasm.